Isadora de Araújo Oliveira

Dr. Isadora de Araújo Oliveira

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2015 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
AVAndréia Vasconcelos-Dos-Santos
Andréia Vasconcelos-Dos-Santos
IOIsadora de Araújo Oliveira
Isadora de Araújo Oliveira
MLMiguel Clodomiro Lucena
Miguel Clodomiro Lucena
NMNatalia Rodrigues Mantuano
Natalia Rodrigues Mantuano
SWStephen A. Whelan
Stephen A. Whelan
ATAdriane Regina Todeschini
Adriane Regina Todeschini
Cancer cells depend on altered metabolism and nutrient uptake to generate and keep the malignant phenotype. The hexosamine biosynthetic pathway (HBP) is a branch of glucose metabolism that produces UDP-GlcNAc, and its derivatives, UDP-GalNAc and CMP-Neu5Ac, donor substrates used in the production of glycoproteins and glycolipids. Growing evidence demonstrates that alteration of the pool of activated substrates might lead to different glycosylation and cell signaling. It is already well established that aberrant glycosylation can modulate tumor growth and malignant transformation in different cancer types. Therefore, biosynthetic machinery involved in the assembly of aberrant glycans are becoming prominent targets for anti-tumor drugs. This review describes three classes of glycosylation, O-GlcNAcylation, N-linked and mucin type O-linked glycosylation, involved in tumor progression, their biosynthesis and highlights the available inhibitors as potential anti-tumor drugs.

1 June 2016 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MLMiguel C. Lucena
Miguel C. Lucena
PCPatricia Carvalho-Cruz
Patricia Carvalho-Cruz
JDJoana L. Donadio
Joana L. Donadio
IOIsadora de Araújo Oliveira
Isadora de Araújo Oliveira
RQRafaela Muniz de Queiroz
Rafaela Muniz de Queiroz
WDWagner Barbosa Dias
Wagner Barbosa Dias
Deregulated cellular metabolism is a hallmark of tumors. Cancer cells increase glucose and glutamine flux to provide energy needs and macromolecular synthesis demands. Several studies have been focused in importance of glycolysis and pentose phosphate pathway. However, a neglected but very important branch of glucose metabolism is the hexosamine biosynthesis pathway (HBP). The HBP is a branch of the glucose metabolic pathway that consumes approximately 2 - 5% of the total glucose, generating UDP-GlcNAc as the end-product. UDP-GlcNAc is the donor substrate used in multiple glycosylation reactions. Thus, HBP links the altered metabolism with aberrant glycosylation providing a mechanism of how cancer cells can sense and respond to microenvironment changes. Here, we investigate the changes of glucose metabolism during epithelial mesenchymal transition (EMT), and the role of O-GlcNAcylation in this process. We show that A549 cells increase glucose uptake during EMT, but instead of increasing the glycolysis and pentose phosphate pathway, the glucose is shunted through the HBP. The activation of HBP induces an aberrant cell surface glycosylation and O-GlcNAcylation. The cell surface glycans display an increase of sialylation α2-6, poly-LacNAc and fucosylation, all known epitopes found in different tumor models. In addition, modulation of O-GlcNAc levels was demonstrated to be important during EMT process. Taken together, our results indicate that EMT is an applicable model to study metabolic and glycophenotype changes during carcinogenesis, suggesting that cell glycosylation senses metabolic changes and modulates cell plasticity.

20 March 2017 in Oncogenesis
Verified
Journal Article
Open access
PDF file
AVA Vasconcelos-Dos-Santos
A Vasconcelos-Dos-Santos
HLH F B R Loponte
H F B R Loponte
NMN R Mantuano
N R Mantuano
IOIsadora de Araújo Oliveira
Isadora de Araújo Oliveira
IPI F de Paula
I F de Paula
ATAdriane Regina Todeschini
Adriane Regina Todeschini
Hyperglycemia is a common feature of diabetes mellitus, considered as a risk factor for cancer. However, its direct effects in cancer cell behavior are relatively unexplored. Herein we show that high glucose concentration induces aberrant glycosylation, increased cell proliferation, invasion and tumor progression of colon cancer. By modulating the activity of the rate-limiting enzyme, glutamine-fructose-6-phosphate amidotransferase (GFAT), we demonstrate that hexosamine biosynthetic pathway (HBP) is involved in those processes. Biopsies from patients with colon carcinoma show increased levels of GFAT and consequently aberrant glycans’ expression suggesting an increase of HBP flow in human colon cancer. All together, our results open the possibility that HBP links hyperglycemia, aberrant glycosylation and tumor malignancy, and suggest this pathway as a potential therapeutic target for colorectal cancer.

1 October 2020 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
NMNatália Rodrigues Mantuano
Natália Rodrigues Mantuano
MSMichal A. Stanczak
Michal A. Stanczak
IOIsadora de Araújo Oliveira
Isadora de Araújo Oliveira
NKNicole Kirchhammer
Nicole Kirchhammer
AFAlessandra A. Filardy
Alessandra A. Filardy
HLHeinz Läubli
Heinz Läubli
Diabetes mellitus (DM) significantly increases the risk for cancer and cancer progression. Hyperglycemia is the defining characteristic of DM and tightly correlates with a poor prognosis in patients with cancer. The hexosamine biosynthetic pathway (HBP) is emerging as a pivotal cascade linking high glucose, tumor progression, and impaired immune function. Here we show that enhanced glucose flow through the HBP drives cancer progression and immune evasion by increasing O-GlcNAcylation in tumor-associated macrophages (TAM). Increased O-GlcNAc skewed macrophage polarization to a M2-like phenotype supporting tumor progression. Finally, we found an upregulation of M2 markers on TAMs in DM2 patients with colorectal cancer compared with nondiabetic normoglycemic patients. Our results provide evidence for a new and targetable mechanism of cancer immune evasion in patients with hyperglycemia, advocating for strict control of hyperglycemia in patients with cancer.

5 March 2019 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
RQRafaela Muniz de Queiroz
Rafaela Muniz de Queiroz
IOIsadora de Araújo Oliveira
Isadora de Araújo Oliveira
BPBruno Piva
Bruno Piva
FCFelipe Bouchuid Catão
Felipe Bouchuid Catão
BRBruno da Costa Rodrigues
Bruno da Costa Rodrigues
WDWagner Barbosa Dias
Wagner Barbosa Dias
The Hexosamine Biosynthetic Pathway (HBP) is a branch of glycolysis responsible for the production of a key substrate for protein glycosylation, UDP-GlcNAc. Cancer cells present altered glucose metabolism and aberrant glycosylation, pointing to alterations on HBP. Recently it was demonstrated that HBP influences many aspects of tumor biology, including the development of metastasis. In this work we characterize HBP in melanoma cells and analyze its importance to cellular processes related to the metastatic phenotype. We demonstrate that an increase in HBP flux, as well as increased O-GlcNAcylation, leads to decreased cell motility and migration in melanoma cells. In addition, inhibition of N- and O-glycosylation glycosylation reduces cell migration. High HBP flux and inhibition of N-glycosylation decrease the activity of metalloproteases 2 and 9. Our data demonstrates that modulation of HBP and different types of glycosylation impact cell migration.

1 January 2012 in Frontiers in Immunology
Verified
Journal Article
Open access
Leonardo Freire-de-LimaLeonardo Freire-de-Lima
Leonardo Freire-de-Lima
IOIsadora de Araújo Oliveira
Isadora de Araújo Oliveira
JNJorge Luiz Neves
Jorge Luiz Neves
LPLuciana L. Penha
Luciana L. Penha
FAFrederico Alisson-Silva
Frederico Alisson-Silva
ATAdriane Regina Todeschini
Adriane Regina Todeschini
Commonly found at the outermost ends of complex carbohydrates in extracellular medium or on outer cell membranes, sialic acids play important roles in a myriad of biological processes. Mammals synthesize sialic acid through a complex pathway, but Trypanosoma cruzi, the agent of Chagas’ disease, evolved to obtain sialic acid from its host through a trans-sialidase (TcTS) reaction. Studies of the parasite cell surface architecture and biochemistry indicate that a unique system comprising sialoglycoproteins and sialyl-binding proteins assists the parasite in several functions including parasite survival, infectivity, and host–cell recognition. Additionally, TcTS activity is capable of extensively remodeling host cell glycomolecules, playing a role as virulence factor. This review presents the state of the art of parasite sialobiology, highlighting how the interplay between host and parasite sialic acid helps the pathogen to evade host defense mechanisms and ensure lifetime host parasitism.